Literature DB >> 21258273

The Oxford classification of IgA nephropathy: single centre experience.

Ladislava Grcevska1, Vesna Ristovska, Vladimir Nikolov, Gordana Petrusevska, Maja Milovanceva-Popovska, Momir Polenakovic.   

Abstract

The Oxford classification for the pathological classification of a glomerular disease in IgA nephropathy was established and published in 2009. Four of the pathological variables: 1) mesangial hypercellularity score, 2) segmental glomerulosclerosis, 3) endocapillary hypercellularity and 4) tubular atrophy/interstital fibrosis were presented as having value in predicting renal outcome in this glomerular disease. These features were recommended to be taken into account for predicting the outcome. In our study, we correlated these four variables with the outcome of the disease in 40 adult patients with IgA nephropathy. Standard histopathologic procedure was used to determine four variables as 0/1. The results were compared with renal outcome, clinical data were obtained from the out-patient files of the patients. The whole follow-up period was 3-27 years. The average survival of the whole group was 10.8±7.47 years (M±SD). Mesangial hypercellularity was confirmed to be associated with the renal outcome (p=0.047), as well as glomerular sclerosis (p=0.009), endocapillary hypercellularity (p=0.001) and tubular atrophy/interstitial fibrosis (p=0.045). When we analysed only patients with a severe form of the disease (nephrotic syndrome; patients treated with immunosuppression), the survival of the patients was associated only with the degree of tubulointerstitial changes (p=0.018). Analysing separately patients with mild clinical form, we found only a predictive value of segmental glomerulosclerosis on renal survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21258273

Source DB:  PubMed          Journal:  Prilozi        ISSN: 0351-3254


  6 in total

1.  Mesangial C4d Deposits in Early IgA Nephropathy.

Authors:  Alfons Segarra; Katheryne Romero; Irene Agraz; Natalia Ramos; Alvaro Madrid; Clara Carnicer; Elias Jatem; Ramón Vilalta; Luis Enrique Lara; Elena Ostos; Naiara Valtierra; Juliana Jaramillo; Karla V Arredondo; Gema Ariceta; Cristina Martinez
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-16       Impact factor: 8.237

2.  Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.

Authors:  Heyan Wu; Xiang Fang; Zhengkun Xia; Chunlin Gao; Yingchao Peng; Xiaojie Li; Pei Zhang; Qianghuining Kuang; Ren Wang; Meiqiu Wang
Journal:  J Nephrol       Date:  2020-06-07       Impact factor: 3.902

3.  Oxford-MEST classification in IgA nephropathy patients: A report from Iran.

Authors:  Hamid Nasri; Mojgan Mortazavi; Ali Ghorbani; Heshmatollah Shahbazian; Soleiman Kheiri; Azar Baradaran; Afsoon Emami-Naieni; Maryam Saffari; Saeed Mardani; Ali Momeni; Yahya Madihi; Milad Baradaran-Ghahfarokhi; Mahmoud Rafieian-Kopaie; Parin Hedayati; Shahzad Baradaran; Mohammadreza Ardalan; Shahram Sajjadieh; Naziheh Assarzadegan; Seyed Mohammad Ahmadi Soleimani; Mohamad Reza Tamadon
Journal:  J Nephropathol       Date:  2012-04-05

4.  Significance of segmental glomerulosclerosis in IgA nephropathy: What is the evidence?

Authors:  Muhammed Mubarak; Hamid Nasri
Journal:  J Renal Inj Prev       Date:  2013-10-10

5.  Association of proteinuria with various clinical findings and morphologic variables of oxford classification in immunoglobulin a nephropathy patients.

Authors:  Hamid Nasri; Yahya Madihi; Alireza Merrikhi; Allaleh Gheissari; Azar Baradaran; Soleiman Kheiri; Mahmoud Rafieian-Kopaei
Journal:  Int J Prev Med       Date:  2013-05

6.  Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.

Authors:  Xuejing Zhu; Huiqiong Li; Yexin Liu; Jing You; Zhong Qu; Shuguang Yuan; Youming Peng; Fuyou Liu; Hong Liu
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.